Mediators of Kidney-Bone Communication in Childhood (PAKC)
Pubertal Assessment of Kidney-Bone Crosstalk
An identified hormone linking bone and kidney function is Fibroblast Growth Factor-23 (FGF23). Data on the variation of FGF23 levels for bone and mineral metabolism in children are scarce. Currently it is assumed that meeting mineral requirements for the skeleton serves the body's overall needs. However, it is not clear as to whether this is true, particularly with growth. The contribution of dietary factors directly linked with the bone/kidney axis through measurement of intake (via 24hr recall) and kidney nutrient clearance (via serum and urinary analysis) will be included in investigations. Findings will serve as a springboard for delineating more specific mechanisms by which these systems become disordered and are influenced by diet. It is expected that adequacy of nutrients known to have a central role in bone function will optimize the hormonal milieu through crosstalk with the kidney.
This effort will allow ongoing investigation in detecting and treating disturbances in mineral metabolism related to kidney disease, specifically in the pediatric population and broaden the understanding of kidney disease itself, as well as that of chronic diseases in which kidney health is of importance, such as diabetes and osteoporosis. Findings of this research may stress the importance of achieving dietary adequacy essential for establishing optimal body composition trajectories, particularly puberty.
研究概览
地位
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Alabama
-
Birmingham、Alabama、美国、35294
- University of Alabama at Birmingham
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Male
- ages 7-11y
- Tanner stage less than or equal to 3 according to the criteria of Marshall and Tanner
Exclusion Criteria:
- History of Cushing's Syndrome, hyperprolactinemia, congenital (non-classic) adrenal hyperplasia, type 1 or 2 diabetes, disturbances in glucose or lipid metabolism
- use of tobacco or consumption of alcohol; thyroid medication, diuretics, beta-blockers, or any medication that potentially could affect body composition, the lipid profile, insulin sensitivity, or blood pressure
- eating disorders, cancer, kidney disease, endocrinopathy, liver disease, heart disease, or thyroid disease.
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
Observation
Healthy early pubertal boys
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Fibroblast Growth Factor 23
大体时间:1 day
|
Fasting plasma measure
|
1 day
|
合作者和调查者
调查人员
- 首席研究员:Krista Casazza, PhD, RD、UAB, Nutrition Sciences
- 研究主任:Orlando M Gutierrez, MD、UAB, Department of Medicine
- 研究主任:Lynae J Hanks, PhD, RD、UAB, Department of Medicine
- 研究主任:Ambika P Ashraf, MD、Children's of Alabama, Pediatric Endocrinology
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- PAKC
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.